SIMCERE PHARMAC. GRP LTD
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its princi… Read more
SIMCERE PHARMAC. GRP LTD (S2P) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, SIMCERE PHARMAC. GRP LTD (S2P) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SIMCERE PHARMAC. GRP LTD - Net Assets Trend (None–None)
This chart illustrates how SIMCERE PHARMAC. GRP LTD's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SIMCERE PHARMAC. GRP LTD (None–None)
The table below shows the annual net assets of SIMCERE PHARMAC. GRP LTD from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to SIMCERE PHARMAC. GRP LTD's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
SIMCERE PHARMAC. GRP LTD Competitors by Market Cap
The table below lists competitors of SIMCERE PHARMAC. GRP LTD ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Top Glove Corporation Bhd
PINK:TPGVF
|
$1.05 Billion |
|
Trinity Capital Inc
NASDAQ:TRIN
|
$1.06 Billion |
|
Superior Plus Corp
PINK:SUUIF
|
$1.06 Billion |
|
Suzhou Hailu Heavy Industry Co Ltd
SHE:002255
|
$1.06 Billion |
|
Bittium Oyj
HE:BITTI
|
$1.05 Billion |
|
Faes Farma SA
MC:FAE
|
$1.05 Billion |
|
PDF Solutions Inc
NASDAQ:PDFS
|
$1.05 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
$1.05 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SIMCERE PHARMAC. GRP LTD's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares SIMCERE PHARMAC. GRP LTD's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently SIMCERE PHARMAC. GRP LTD utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares SIMCERE PHARMAC. GRP LTD's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SIMCERE PHARMAC. GRP LTD (S2P) | €- | N/A | N/A | $1.05 Billion |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |